名字:胡立庆
照片:
![](/__local/0/18/76/26E313466FB084F15C01A18E617_009AB900_2B341.png)
职称:讲师
导师:药物化学(学术硕士学位点),生物与医药(专业硕士学位点)
电子邮箱:huliqing@hunnu.edu.cn
通讯地址:湖南省长沙市岳麓区桐梓坡路371号,邮编:410013
办公室地址:湖南师范大学咸嘉湖校区新综合楼514室
简介:
胡立庆,汉族,硕士生导师。2022年毕业于中南大学湘雅药学院药物化学专业,获得医学博士学位,同年8月加入吕氏贵宾会0022药学系和“小分子靶向药物研究与创制”湖南省重点实验室,长期从事小分子药物的设计、合成与生物活性研究工作,主持和参与国家自然科学基金和省部级课题4项。以第一作者或通讯作者身份在Nature Communications、Journal of Medicinal Chemistry、European Journal of Medicinal Chemistry、Drug Discovery Today、Respiratory Research、Vascular Pharmacology、Bioorganic Chemistry等国际权威杂志发表SCI学术论文10余篇,单篇影响因子最高16.6;自主研发的候选药物HLQ2g已实现成果转化,转让金额高达3000万元(项目名称:抗肺动脉高压创新药物LXH-1211研发,合同编号:YJY20095),推进了新药临床转化进程;围绕疾病发展进程中的关键调控分子热休克蛋白110(Heat shock protein110, Hsp110),开展了系列原创性研究,寻找到首个Hsp110变构抑制剂HLQ2h,推动了原创药物研发。
主持的科研项目:
1.湖南省自然科学基金青年项目,2023JJ40458,新型真菌Hsp110/HDAC双靶点抑制剂的发现与抗耐药真菌作用研究,2023-01至2025-12,5万元,主持;
2.湖南省教育厅,优秀青年项目,23B0041,Hsp110抑制剂的结构优化与抗耐药真菌作用研究,2024-01至2026-12,3万元,主持。
代表性学术论文:
1.Liu W, Deng W,Hu L*, Zou H*.Advancesin TRPV6 inhibitors for tumors by targeted therapies: Macromolecular proteins, synthetic small molecule compounds, and natural compounds.Eur J Med Chem,2024,270:116379. (IF:6.7)
2.Zhao C, Le X, Li M, Hu Y, Li X, Chen Z, Hu G,Hu L*, Li Q*.Inhibition of Hsp110-STAT3 interaction in endothelial cells alleviates vascular remodeling in hypoxic pulmonary arterial Hypertension model.Respir Res,2023,24(1):289. (IF:5.8)
3.Hu L#, Sun C#, Li H, Kidd J, Zhou L, Li Q, Liu Q*. A first-in-class inhibitor of Hsp110 molecular chaperones of pathogenic fungi.NatureCommunications,2023, 14: 2745.(IF:16.6)
4.Hu L, Zhao C, Chen Z, Hu G, Li X*, Li Q*.An emerging strategy for targeted therapy of pulmonary arterial hypertension: vasodilation plus vascular remodeling inhibition.Drug Discov Today,2022, 27(5):1457-1463.(Q1, IF:8.37)
5.Hu L#, Wang G#, Zhao C, Peng Z, Tao L, Chen Z, Hu G, Li Q*. Identification of selective homeodomain interacting protein kinase 2 inhibitors, a potential treatment for renal fibrosis.Bioorg Chem,2022,126: 105866. (Q1, IF :5.31)
6. Zhao C#,Hu L#, He X, Li L, Yin M,Tettey AT, Wang Y, Shen J, Tang S,Wu C,Li Q, Wang Z*, Li X*. TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats.Vascul Pharmacol, 2022, 145:107017. (Q1, IF :5.74)
7.Hu L, Li L, Chang Q, Fu S, Qin J, Chen Z, Li X, Liu Q, Hu G, Li Q*. Discovery of novel pyrazolo [3,4-b] pyridine derivatives with dual activities of vascular remodeling inhibition and vasodilation for the treatment of pulmonary arterial hypertension.J Med Chem,2020, 63(19):11215-11234. (Q1, IF:8.04,Top 1)